ABSTRACT
AIM:
To compare the
clinical efficacy of conbercept and aflibercept in the
treatment of wet
age-related macular degeneration(wARMD)based on 4 consecutive
intravitreal injections.
METHODS:
The clinical data of 108
patients(108
eyes)
who were diagnosed as wARMD and treated with
intravitreal injection at our
hospital from January 2019 to January 2021 were retrospectively analyzed. They were divided into conbercept group(54 cases, 54
eyes)and aflibercept group(54 cases, 54
eyes)according to the different
injectable drugs. All
patients received
intravitreal injection once a month, with four consecutive
injections. Follow up for 12mo to observe best corrected
visual acuity(BCVA), central macular thickness(CMT),
complications and
recurrence before and after
injection.
RESULTS:
BCVA and CMT of
patients in the two groups at 1, 2, 5 and 8mo after
injection had no between-group differences(P>0.05), but both were significantly improved compared with those before
injection(P<0.05). By the end of follow-up, conjunctival
hemorrhage occurred in 2
eyes of the conbercept group at the early stage, and increased
intraocular pressure and conjunctival
hemorrhage occurred respectively in 2
eyes of the aflibercept group. There were no serious
complications related to
drug injection such as
retinal detachment, complicated
cataract,
endophthalmitis and
retinal pigment epithelial
tear in the two groups, and there was no difference in the
recurrence rate between the two groups(7% vs. 6%, P=1.000).
CONCLUSION:
On the basis of continuous 4 times of
intravitreal injection, both conbercept and aflibercept are safe and effective in the
treatment of wARMD, and the
efficacy is even.